Icosapent Ethyl
Amarin Pharmaceutical
[]
fantastic discussion of the #respectepa trial by . #aha22 still a role to consider epa to address residual risk in secondary prevention patients. 
Johns Hopkins Medicine. Associate Professor, Cardiology. Co-Editor in Chief @AJPCardio. #WomenHeartHealth #CardioObstetrics #cvPrev #echofirst She/her #BeKind